Leslie Lu'un ücretlendirmesi EC Healthcare'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-HK$12m
Jun 30 2024	n/a	n/a	-HK$15m
Mar 31 2024	HK$5m	HK$5m	-HK$19m
Dec 31 2023	n/a	n/a	-HK$11m
Sep 30 2023	n/a	n/a	-HK$4m
Jun 30 2023	n/a	n/a	HK$33m
Mar 31 2023	HK$21m	HK$4m	HK$70m
Dec 31 2022	n/a	n/a	HK$93m
Sep 30 2022	n/a	n/a	HK$117m
Jun 30 2022	n/a	n/a	HK$157m
Mar 31 2022	HK$13m	HK$2m	HK$198m

Tazminat ve Piyasa: Leslie 'nin toplam tazminatı ($USD 619.35K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 230.08K ).

Tazminat ve Kazançlar: Leslie 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Leslie Lu (44 yo)

1.2yrs

Görev süresi

HK$4,818,000

Tazminat

Mr. Lyn Wade Lu, also known as Leslie, served as Co-Chief Executive Officer & Executive Director at EC Healthcare since August 23, 2021 until November 1, 2023. He serves as Chief Executive Officer at EC He...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chi Fai Tang	Founder & Executive Chairman	9.2yrs	HK$1.24m	60.93% HK$ 447.8m
Lyn Wade Lu	Chief Executive Officer & Executive Director	1.2yrs	HK$4.82m	Veri yok
Heung Wing Lee	CFO & Executive Director	5.5yrs	HK$3.77m	0.057% HK$ 421.9k
Tai Cheung Wong	Chief Operating Officer	2.5yrs	Veri yok	Veri yok
Kelly Tsang	Associate Director of Accounting	no data	Veri yok	Veri yok
Kin Keung Chan	Chief Public Affairs Officer & Chief Dental Officer	2.5yrs	Veri yok	Veri yok
Katy Ip	Sales Director	no data	Veri yok	Veri yok
Chun Pu Chu	Chief Business Officer	4.3yrs	Veri yok	Veri yok
Chun Yu Chan	Chief Talent Officer	2.5yrs	Veri yok	Veri yok
Julie Chow	Chief Proposition Officer of Healthcare	2yrs	Veri yok	Veri yok
Chun Pong Siu	Company Secretary	7.3yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: 2138 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chi Fai Tang	Founder & Executive Chairman	9.2yrs	HK$1.24m	60.93% HK$ 447.8m
Lyn Wade Lu	Chief Executive Officer & Executive Director	3.4yrs	HK$4.82m	Veri yok
Heung Wing Lee	CFO & Executive Director	5yrs	HK$3.77m	0.057% HK$ 421.9k
Ching Nam Ma	Independent Non-Executive Director	8.9yrs	HK$240.00k	0.025% HK$ 186.0k
Andrew Look	Independent Non-Executive Director	8.9yrs	HK$220.00k	Veri yok
Kun Shing Luk	Non Executive Director	9.3yrs	HK$126.00k	0.24% HK$ 1.8m
Tsun Au	Independent Non-Executive Director	2.3yrs	HK$120.00k	Veri yok
Shih Ti Yang Leung	Non-Executive Director	less than a year	Veri yok	0.65% HK$ 4.8m

7.0yrs

Ortalama Görev Süresi

44.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2138 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/08 17:42
Gün Sonu Hisse Fiyatı	2025/01/08 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

EC Healthcare 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tingting Li	BOCI Research Ltd.
Zhuonan Xu	China International Capital Corporation Limited
null null	China International Capital Corporation Limited

EC Healthcare Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

EC Healthcare, Annual General Meeting, Aug 23, 2024

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

EC Healthcare Announces Executive Changes

EC Healthcare, Annual General Meeting, Aug 23, 2023

Less than half of directors are independent

Recent updates

New minor risk - Market cap size

Upcoming dividend of HK$0.01 per share

EC Healthcare (HKG:2138) Shares Fly 29% But Investors Aren't Buying For Growth

Dividend of HK$0.01 announced

First half 2025 earnings released: EPS: HK$0.012 (vs HK$0.006 in 1H 2024)

EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025

New minor risk - Market cap size

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024

Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024

Price target increased by 35% to HK$2.84

Less than half of directors are independent

Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding

EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare, Annual General Meeting, Aug 23, 2024

EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024

An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.

EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement

When Should You Buy EC Healthcare (HKG:2138)?

Is EC Healthcare (HKG:2138) A Risky Investment?

New minor risk - Share price stability

EC Healthcare (SEHK:2138) entered into sale and purchase agreement to acquire 6.49% stake in Pangenia Inc from Sharp Point Consultant Limited for HKD 17.4 million.

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

Price target decreased by 15% to HK$5.22

First half 2024 earnings released: EPS: HK$0.006 (vs HK$0.068 in 1H 2023)

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023

EC Healthcare Announces Executive Changes

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023

Upcoming dividend of HK$0.042 per share at 2.6% yield

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023

Is EC Healthcare (HKG:2138) Using Too Much Debt?

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Consensus EPS estimates fall by 31%

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Price target decreased by 11% to HK$8.03

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare, Annual General Meeting, Aug 23, 2023

EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

Is EC Healthcare (HKG:2138) Potentially Undervalued?

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Price target increased to HK$9.33

Price target increased to HK$8.04

Upcoming dividend of HK$0.058 per share

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Investor sentiment improved over the past week

Consensus forecasts updated

First half 2023 earnings released

EC Healthcare Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 20 January 2023

Price target decreased to HK$8.89

Less than half of directors are independent

EC Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2022

EC Healthcare to Report Q2, 2023 Results on Nov 24, 2022

Investor sentiment improved over the past week

Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?